🆙#ESMO26 Presidential Symposium II: #LCSM 🔥SAFFRON: Osimertinib (Osi) + Savolitinib (Savo) vs Platinum–Pemetrexed (Plat–Pem) in EGFRm MET-Overexpressed (OE) and/or -Amplified (AMP) Advanced NSCLC Post-Osi: Phase (Ph) 3 Primary Results 🎙️Dr. Shun Lu 🔢LBA6 🎯Post-Progression Re-biopsy Mandated 🎯35% of Patients Evaluable for MET testing had MET overexpression (IHC3+ ≥90%) and/or MET amplification (FISH 10+) 🎯Significantly Improved BICR-PFS (7.6 vs 5.4mo, HR 0.55; n=338) and OS (17.8 vs 12.9mo, HR 0.68, p=0.010) 🎯Grade≥3 TEAEs 64% vs 63%; Discontinuation 14% vs 8% ☑️NCT05261399 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters